CoChat

Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Background: Body weight (BW) loss is an essential therapeutic goal in type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their effect on body composition has not yet been fully explored. The study aim was to assess the impact of Semaglutide on body composition in patients with T2D. Methods: Forty patients with T2D were treated with subcutaneous Semaglutide and evaluated at the baseline (T0) and after three (T3) and six (T6) months. Body composition was assessed by a phase-sensitive bioimpedance analyzer. Visceral adipose tissue (VAT) thickness was also measured with an ultrasonographic method (US-VAT). Anthropometric variables, muscular strength, and laboratory tests were analyzed and compared. Results: A significant decrease in VAT, the fat mass index (FMI), and BW loss was observed at all observation times. US-VAT, the skeletal mass index (SMI), the fat-free mass index (FFMI), waist circumferences, and glycated hemoglobin had lessened after three months and remained stable at T6. No variations in muscle strength, the muscle quality index, and body water were found. Discussion: In a real-life setting, Semaglutide provided significant weight loss mainly due to a reduction in the FMI and VAT, with non-clinically relevant changes in the SMI, the FFMI, and muscle strength. Most importantly, the results were obtained after three months of treatment and persisted thereafter.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nu14122414

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mean changes in VAT (L) and US-VAT (cm) throughout the study period. Means are reported as least squared means estimated by mixed model analysis. * p < 0.05; ** p < 0.01; n.s.: not significant; VAT: visceral adipose tissue; US-VAT: ultrasonographic visceral adipose tissue.
Figure 1 Mean changes in VAT (L) and US-VAT (cm) throughout the study period. Means are reported as least squared means estimated by mixed model analysis. * p < 0.05; ** p < 0.01; n.s.: not significant; VAT: visceral adipose tissue; US-VAT: ultrasonographic visceral adipose tissue.CC BY · PubMed Central
Figure 2 Mean changes in fat mass index, skeletal muscle index, and fat-free mass index throughout the study period. Means are reported as least squared means estimated by mixed model analysis. * p < 0.05; ** p < 0.01; n.s.: not significant.
Figure 2 Mean changes in fat mass index, skeletal muscle index, and fat-free mass index throughout the study period. Means are reported as least squared means estimated by mixed model analysis. * p < 0.05; ** p < 0.01; n.s.: not significant.CC BY · PubMed Central
Figure 3 Graphical representation of the percentage of weight loss for each participant. (N= 40) from baseline to week 26. Responders were defined as participants achieving a body weight loss of 5% or more after six months of treatment.
Figure 3 Graphical representation of the percentage of weight loss for each participant. (N= 40) from baseline to week 26. Responders were defined as participants achieving a body weight loss of 5% or more after six months of treatment.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 67

Metadata

Authors
Volpe, S., Lisco, G., Racaniello, D., Fanelli, M., Colaianni, V., Vozza, A., Triggiani, V., Sabbà, C., Tortorella, C., De Pergola, G., & Piazzolla, G.
Affiliations
  • University of Bari Aldo Moro (IT)
  • Unit of Internal Medicine and Geriatrics, National Institute of Gastroenterology IRCCS “Saverio de Bellis” Research Hospital, Castellana Grotte, Via Turi 27, 70013 Bari, Italy
Corresponding author
Piazzolla, Giuseppina
Venue
Nutrients
Publisher
MDPI AG
Published
2022-06-10
Volume
14
Issue
12
Pages
2414
ISSN
2072-6643 (ISSN-L)
OpenAlex
W4282558207
Cited by
67
References
36
Citations by year
2026: 17 · 2025: 15 · 2024: 23 · 2023: 10 · 2022: 2
FWCI
9.27
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
semaglutide, type 2 diabetes, body composition, weight loss, GLP-1 receptor agonists, visceral adipose tissue, fat mass index, fat-free mass index, skeletal muscle mass, muscle strength, HbA1c, bioelectrical impedance analysis, ultrasonography
MeSH terms
Semaglutide, Body Composition, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Prospective Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study. https://app.cochat.ai/papers/10.3390/nu14122414
The paper
Volpe, S., Lisco, G., Racaniello, D., Fanelli, M., Colaianni, V., Vozza, A., Triggiani, V., Sabbà, C., Tortorella, C., De Pergola, G., & Piazzolla, G. (2022). Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study. Nutrients. https://doi.org/10.3390/nu14122414

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.